FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

Completed · Early Phase 1

Conditions studied: Breast Cancer

In brief

This study has been designed to help us determine if FACBC PET or PEM can accurately evaluate how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or PEM can accurately measure your response to chemotherapy.

Key facts

Study ID

NCT01864083

Run by

Memorial Sloan Kettering Cancer Center

People needed

30

Starts

2013-05-01

Expected to finish

2017-08-29

Last updated by the study team

2017-08-31

Who can join

Age: 21 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women presenting for evaluation at MSKCC with biopsy proven primary IDC or ILC
• No prior therapy for IDC or ILC
• Clinical need for local disease staging with breast MR (Group A only)
• Clinical need for neoadjuvant chemotherapy (Group B only)
• Patients must provide written informed consent

You may not qualify if…

• Age <21 years
• Men
• Pregnancy or lactation
• Patients who have already started treatment for the current malignancy
• Patients who cannot undergo PET scanning (i.e. because of weight limits)
• Patients who are known to have contraindication for MRI (e.g. metal implants)
• Patients may only participate in group #1 or group #2, but not both

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.